Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Transparency Policies Not Suited To Generics, GPhA Argues

Executive Summary

Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.


Related Content

The US Drug Pricing Hearing Pharma Wants
GPhRMA? Generic Trade Group Picks Up Another Exec From Brand Association
EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
Formalizing 'Name And Shame': New Strategy To Rein In Price Increases
Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says
The Clinton Drug Price Board, 23 Years Later
Allergan's Price Reform Pledge: Will Others Follow?
For Generics Industry, Will Larger Firms Mean Weaker Lobbying?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts